Research statistics

Sermorelin research: publications and trials

What has been published on Sermorelin: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Sermorelin works or is safe. For what it is and what the studies found, see the Sermorelin profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

373

Since 1984

Publications in 2026 so far

4

Through November 15, 2026

Human clinical research

23.7%

87 of 367 classified

Registered clinical trials

0

ClinicalTrials.gov

Randomized controlled trials

19

Publications reporting an RCT in people

Systematic reviews and meta-analyses

0

Preclinical studies

71.7%

191 animal · 70 in vitro · 2 computational

Records that only mention it

75

Not counted above

Status in the library: Research only. Groups: Growth hormone axis. 6 publications are not yet classified by study type.

What to keep in mind

  • More than 70% of the indexed publications are animal, cell or computational studies.

Publications by year

Sermorelin publications by year and evidence

1984, Human clinical research: 3 of 81984, Preclinical (animal, in vitro, computational): 5 of 81985, Human clinical research: 3 of 131985, Preclinical (animal, in vitro, computational): 10 of 131986, Human clinical research: 12 of 181986, Preclinical (animal, in vitro, computational): 5 of 181986, Reviews and meta-analyses: 1 of 181987, Human clinical research: 7 of 211987, Preclinical (animal, in vitro, computational): 12 of 211987, Other and not yet classified: 2 of 211988, Human clinical research: 6 of 221988, Preclinical (animal, in vitro, computational): 13 of 221988, Other and not yet classified: 3 of 221989, Human clinical research: 8 of 151989, Preclinical (animal, in vitro, computational): 7 of 151990, Human clinical research: 9 of 211990, Preclinical (animal, in vitro, computational): 12 of 211991, Human clinical research: 1 of 211991, Preclinical (animal, in vitro, computational): 20 of 211992, Human clinical research: 1 of 171992, Preclinical (animal, in vitro, computational): 15 of 171992, Other and not yet classified: 1 of 171993, Human clinical research: 7 of 121993, Preclinical (animal, in vitro, computational): 5 of 121994, Human clinical research: 3 of 81994, Preclinical (animal, in vitro, computational): 4 of 81994, Reviews and meta-analyses: 1 of 81995, Human clinical research: 4 of 111995, Preclinical (animal, in vitro, computational): 7 of 111996, Human clinical research: 7 of 141996, Preclinical (animal, in vitro, computational): 7 of 141997, Human clinical research: 5 of 141997, Preclinical (animal, in vitro, computational): 7 of 141997, Reviews and meta-analyses: 1 of 141997, Other and not yet classified: 1 of 141998, Human clinical research: 3 of 81998, Preclinical (animal, in vitro, computational): 5 of 81999, Human clinical research: 2 of 91999, Preclinical (animal, in vitro, computational): 5 of 91999, Reviews and meta-analyses: 1 of 91999, Other and not yet classified: 1 of 92000, Human clinical research: 1 of 92000, Preclinical (animal, in vitro, computational): 8 of 92001, Preclinical (animal, in vitro, computational): 3 of 32002, Preclinical (animal, in vitro, computational): 1 of 12003, Preclinical (animal, in vitro, computational): 6 of 72003, Reviews and meta-analyses: 1 of 72004, Human clinical research: 1 of 52004, Preclinical (animal, in vitro, computational): 4 of 52005, Human clinical research: 1 of 72005, Preclinical (animal, in vitro, computational): 6 of 72006, Human clinical research: 1 of 32006, Preclinical (animal, in vitro, computational): 1 of 32006, Other and not yet classified: 1 of 32007, Preclinical (animal, in vitro, computational): 3 of 32008, Preclinical (animal, in vitro, computational): 7 of 72009, Preclinical (animal, in vitro, computational): 3 of 32010, Preclinical (animal, in vitro, computational): 7 of 72011, Preclinical (animal, in vitro, computational): 9 of 102011, Other and not yet classified: 1 of 102012, Preclinical (animal, in vitro, computational): 12 of 132012, Reviews and meta-analyses: 1 of 132013, Preclinical (animal, in vitro, computational): 2 of 22014, Preclinical (animal, in vitro, computational): 3 of 32015, Preclinical (animal, in vitro, computational): 4 of 42016, Human clinical research: 1 of 62016, Preclinical (animal, in vitro, computational): 5 of 62017, Human clinical research: 1 of 52017, Preclinical (animal, in vitro, computational): 3 of 52017, Other and not yet classified: 1 of 52018, Preclinical (animal, in vitro, computational): 5 of 52019, Preclinical (animal, in vitro, computational): 2 of 22020, Preclinical (animal, in vitro, computational): 5 of 72020, Reviews and meta-analyses: 1 of 72020, Other and not yet classified: 1 of 72021, Preclinical (animal, in vitro, computational): 8 of 82022, Preclinical (animal, in vitro, computational): 4 of 42023, Preclinical (animal, in vitro, computational): 6 of 62024, Preclinical (animal, in vitro, computational): 3 of 42024, Reviews and meta-analyses: 1 of 42025, Preclinical (animal, in vitro, computational): 2 of 32025, Other and not yet classified: 1 of 32026 (to date), Preclinical (animal, in vitro, computational): 2 of 42026 (to date), Reviews and meta-analyses: 2 of 4Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified010203019841993200220112026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
198435008
19853100013
19861251018
19877120221
19886130322
1989870015
19909120021
19911200021
19921150117
1993750012
199434108
1995470011
1996770014
1997571114
199835008
199925119
200018009
200103003
200201001
200306107
200414005
200516007
200611013
200703003
200807007
200903003
201007007
2011090110
20120121013
201302002
201403003
201504004
201615006
201713015
201805005
201902002
202005117
202108008
202204004
202306006
202403104
202502013
2026 (to date)02204

Study types

Animal study191
In vitro study70
Other clinical trial58
Randomized controlled trial19
Review10
Observational human study9
Editorial, letter or other7
Not yet classified6
Computational study2
Case report1

Research areas

From MeSH major topics. A paper can be in several areas.

Endocrinology169
Neurological and mental health85
Oncology84
Reproductive and sexual health49
Metabolic health33
Longevity and aging18
Obesity and weight management18
Immune system16
Cardiovascular15
Gastrointestinal12
Dermatology11
Musculoskeletal8

Registered clinical trials

A registration is not a result.

No registered trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.

    European journal of endocrinology · August 1, 2005 · Randomized controlled trial · cited 11 times

    PMID 16061831 · DOI 10.1530/eje.1.01965 · Human clinical research

  2. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep.

    European journal of endocrinology · November 1, 2004 · Randomized controlled trial · cited 16 times

    PMID 15538933 · DOI 10.1530/eje.0.1510561 · Human clinical research

  3. The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency.

    European journal of endocrinology · April 1, 2000 · Randomized controlled trial · cited 20 times

    PMID 10754477 · DOI 10.1530/eje.0.1420359 · Human clinical research

  4. Quantitative growth hormone secretion and final adult height.

    Clinical endocrinology · November 1, 1999 · Randomized controlled trial · cited 1 times

    PMID 10594520 · DOI 10.1046/j.1365-2265.1999.00844.x · Human clinical research

  5. The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals.

    Clinical endocrinology · November 1, 1999 · Randomized controlled trial · cited 10 times

    PMID 10594518 · DOI 10.1046/j.1365-2265.1999.00839.x · Human clinical research

  6. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation.

    The Journal of clinical endocrinology and metabolism · April 1, 1998 · Randomized controlled trial · cited 97 times

    PMID 9543138 · DOI 10.1210/jcem.83.4.4711 · Human clinical research

  7. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women.

    The Journal of clinical endocrinology and metabolism · November 1, 1997 · Randomized controlled trial · cited 37 times · open access

    PMID 9360512 · DOI 10.1210/jcem.82.11.4363 · Human clinical research

  8. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.

    The Journal of clinical endocrinology and metabolism · May 1, 1997 · Randomized controlled trial · cited 54 times

    PMID 9141536 · DOI 10.1210/jcem.82.5.3943 · Human clinical research

  9. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature.

    Metabolism: clinical and experimental · September 1, 1995 · Randomized controlled trial · cited 21 times

    PMID 7666796 · DOI 10.1016/0026-0495(95)90016-0 · Human clinical research

  10. GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers.

    Clinical endocrinology · September 1, 1995 · Randomized controlled trial · cited 22 times

    PMID 7586605 · DOI 10.1111/j.1365-2265.1995.tb02042.x · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture.

    Endocrinology · June 1, 1989 · Animal study · cited 297 times

    PMID 2541999 · DOI 10.1210/endo-124-6-2791 · Animal studies

  2. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors.

    Endocrinology · February 1, 1992 · Animal study · cited 232 times

    PMID 1346381 · DOI 10.1210/endo.130.2.1346381 · Animal studies

  3. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.

    Endocrinology · June 1, 1985 · Animal study · cited 154 times

    PMID 2859987 · DOI 10.1210/endo-116-6-2643 · Animal studies

  4. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.

    Clinical endocrinology · December 1, 1987 · Other clinical trial · cited 118 times

    PMID 2901302 · DOI 10.1111/j.1365-2265.1987.tb02957.x · Human clinical research

  5. Super-active analogs of growth hormone-releasing factor (1-29)-amide.

    Biochemical and biophysical research communications · February 1, 1984 · Animal study · cited 115 times

    PMID 6231028 · DOI 10.1016/0006-291x(84)91647-4 · Animal studies

Latest publications

  1. Cardiomyocyte-specific expression of HIF-1α mediates the cardioprotective effects of growth hormone-releasing hormone.

    American journal of physiology. Heart and circulatory physiology · August 1, 2026 · Animal study · cited 0 times · open access

    PMID 42541513 · DOI 10.1152/ajpheart.00118.2026 · Animal studies

  2. Growth hormone - releasing hormone antagonists protect endothelial corneal cells against lipopolysaccharides-induced inflammation.

    Experimental eye research · July 15, 2026 · In vitro study · cited 1 times

    PMID 42456877 · DOI 10.1016/j.exer.2026.111168 · In vitro studies

  3. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

    Frontiers in endocrinology · June 18, 2026 · Review · cited 1 times · open access

    PMID 42395176 · DOI 10.3389/fendo.2026.1822475 · Reviews and meta-analyses

  4. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Sports medicine (Auckland, N.Z.) · April 12, 2026 · Review · cited 8 times · open access

    PMID 41966639 · DOI 10.1007/s40279-026-02437-0 · Reviews and meta-analyses

  5. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

    Journal of pharmaceutical and biomedical analysis · October 20, 2025 · Editorial, letter or other · cited 1 times

    PMID 41138283 · DOI 10.1016/j.jpba.2025.117207 · Commentary and other

  6. Growth hormone - releasing hormone antagonists induce autophagy in cancer cells.

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · October 9, 2025 · In vitro study · cited 1 times

    PMID 41075421 · DOI 10.1016/j.ghir.2025.101668 · In vitro studies

  7. Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.

    International journal of molecular sciences · April 1, 2025 · In vitro study · cited 1 times · open access

    PMID 40244089 · DOI 10.3390/ijms26073267 · In vitro studies

  8. Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.

    International journal of molecular sciences · October 18, 2024 · Animal study · cited 2 times · open access

    PMID 39456984 · DOI 10.3390/ijms252011200 · Animal studies

  9. A novel approach for the treatment of AML, through GHRH antagonism: MIA-602.

    Reviews in endocrine & metabolic disorders · October 17, 2024 · Review · cited 3 times · open access

    PMID 39417961 · DOI 10.1007/s11154-024-09917-6 · Reviews and meta-analyses

  10. Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.

    Oncotarget · April 8, 2024 · Animal study · cited 7 times · open access

    PMID 38588464 · DOI 10.18632/oncotarget.28579 · Animal studies

Browse all 373 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: GRF 1-29; Groliberin; Semorelin; Sermorelin; Sermorelina; Sermoreline; Sermorelinum; Sermorlin

((TITLE_ABS:"GRF 1-29" OR CHEM:"GRF 1-29" OR TITLE_ABS:"GRF1-29" OR CHEM:"GRF1-29") OR (TITLE_ABS:"Groliberin" OR CHEM:"Groliberin") OR (TITLE_ABS:"Semorelin" OR CHEM:"Semorelin") OR (TITLE_ABS:"Sermorelin" OR CHEM:"Sermorelin") OR (TITLE_ABS:"Sermorelina" OR CHEM:"Sermorelina") OR (TITLE_ABS:"Sermoreline" OR CHEM:"Sermoreline") OR (TITLE_ABS:"Sermorelinum" OR CHEM:"Sermorelinum") OR (TITLE_ABS:"Sermorlin" OR CHEM:"Sermorlin")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Sermorelin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/sermorelin